Spinal Muscular Atrophy: 
Adult Care Pathway

The original version of the SMA Adult Care Pathway (published Aug 2021) was supported by sponsorship from Biogen Idec Ltd. Biogen Idec Ltd has had no control over the educational content of the original or updated version of the SMA Adult Care Pathway.

This updated version (published Jul 2022) of the SMA Adult Care Pathway has been supported by a grant from Roche Products Limited. Roche Products Limited has had no control over the content other than a factual accuracy check.
About this pathway

This integrated care pathway has been created as a collaborative effort – our special thanks to the spinal muscular atrophy (SMA) professionals representing a range of specialist SMA centres who contributed to this project. We hope the pathway will be a useful resource locally for both healthcare professionals and providers to map the SMA journey and best practice care. We are particularly keen to share this resource and receive comments in order to ensure the pathway is as comprehensive as possible.

Currently awareness of SMA and access to SMA services across the UK is variable. As a result many individuals may wait too long for reviews and assessment which can have major ramifications for their symptom management and quality of life. It is essential that the complexity of SMA care is understood in order to make the most meaningful improvements to local services. We hope this integrated care pathway will help to unravel the SMA journey and aid you in improving and streamlining the care delivered in your area.

Standards of care are already available but granularity around the patient journey is important for specialists and generalists so that they can understand the care adults with SMA are likely to need throughout their journey. If the pathway is explicit, then:

- Patient journey is smoother
- Teams can ensure the right care is delivered at the right time.

International Standards of Care

- Part 1: Diagnosis and management of spinal muscular atrophy: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care – ScienceDirect
- Part 2: Diagnosis and management of spinal muscular atrophy: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics - ScienceDirect

The SMA integrated care pathway is easy to navigate by clicking on the menu tabs.

Click on icons in the pathway to open further information:

- Information
- Red flag & alerts
- Sub pathway

The pathway is designed to be viewed electronically. Some links redirect to resources that will open in your internet browser – these will require an internet connection.

Review date September 2023
About SMA

Spinal muscular atrophies (SMA) include a group of neuromuscular disorders characterised by degeneration of alpha motor neurons in the spinal cord with progressive muscle atrophy, weakness and paralysis. The most common form of SMA is due to a defect in the survival motor neuron 1 (SMN1) gene localised to 5q11.2-q13.3. It includes a wide range of phenotypes that are classified into clinical groups on the basis of age of onset and maximum motor function achieved.

Approximately 1 in 40 people carry an SMA-associated genetic mutation in the survival motor neurone 1 gene (SMN1) leading to an insufficient production of full length SMA protein. As a result 1:10,000 infants is born with the condition. The majority of infants with SMA have the most severe form of the disease (SMA I) in which symptoms manifest in the first few weeks or months of life. Milder forms of the disease also exist, e.g. SMA II, III and IV, which are associated with later onset and better prognosis.

Management of SMA

SMA is managed through multidisciplinary supportive care. Treatment should follow guidelines from the International Standards of Care Committee for Spinal Muscular Atrophy. Supportive care strategies aim to minimise the impact of disability, address complications and improve quality of life. These may involve respiratory, gastroenterology, and orthopaedic care, as well as nutritional support, physiotherapy, assistive technologies, occupational therapy and social care. New treatments now present opportunities to change the management and survival landscape of SMA.

Treatment expectations

Treatment expectations are subjective and based on each individual patient. To make sure the right treatment expectations are set a broad and holistic understanding of each patient’s needs is required. These relate to: treatment access, access to supportive care, education level, geography, social isolation, information, peer-to-peer exchange and access to technology.

What does it mean for patients and carers?

- Functional improvement from baseline – any improvement is good. SMA is a deteriorating disease, so even stabilisation is seen as beneficial.
- Reduced manifestations.
- Improved life expectancy and stabilisation.

<table>
<thead>
<tr>
<th>Treatment expectations for emerging phenotypes:</th>
<th>SMA I</th>
<th>SMA II</th>
<th>SMA III (childhood onset)</th>
<th>SMA IV (adulthood onset)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shortened life expectancy without treatment</td>
<td></td>
<td></td>
<td>Normal life expectancy</td>
<td></td>
</tr>
</tbody>
</table>
Acknowledgements

Our thanks to the following individuals who contributed to the development of the integrated care pathway:

• Hayley Davis, Neuromuscular physiotherapist, Cardiff and Vale University Health Board
• Rebecca Flesher, Occupational therapist, The Walton Centre NHS Foundation Trust, Liverpool
• Dr Clare Galtrey, Consultant neurologist, St George’s Hospital London
• Dr Channa Hewamadduma, Neuromuscular physician, Sheffield Teaching Hospitals NHS Foundation Trust
• Natasha Hoyle, Neurosciences pharmacist, Sheffield Teaching Hospitals NHS Foundation Trust
• Dr James Lilleker, Neurology consultant, Salford Royal NHS Foundation Trust, Salford
• Lindsay Maidment, Neuromuscular clinical specialist physiotherapist, Sheffield Teaching Hospitals NHS Foundation Trust
• Dr Chiara Marini-Bettolo, Consultant neurologist, John Walton Muscular Dystrophy Research Centre, Newcastle
• Dr Andria Merrison, Consultant neurologist, North Bristol NHS Trust, Bristol
• Robert Muni-Lofra, Consultant physiotherapist, John Walton Muscular Dystrophy Research Centre, Newcastle
• Sun Narayan, Neuromuscular specialist physiotherapist and clinical coordinator, University Hospital Southampton NHS Foundation Trust
• Derek Weidner Independent Pharmacist Prescriber St George’s Hospital London

Facilitator
• Sue Thomas, Independent Healthcare Consultant

Pathway design
• Sarah Mehta, Medical Writer

Contact us
Please contact us with your comments and feedback at: info@neurologyacademy.org

Document due for review in September 2023.
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.
Established diagnosis

Suspected adult presentation (progressive neuromuscular weakness but not identified as SMA)

Referral for confirmation of diagnosis or treatment assessment

Assessment at NM centre to see if patient suitable to treat

Assessment by: neurologist, neuromuscular consultant, Respiratory assessment Physiotherapist, CT scan

MDT discussion re first-line treatment options

Follow-up discussion about treatment options; patient willing to consider treatment

Psychological support

SMA REACH criteria

Patient consents to enrolment on MAA and SMA REACH

Baseline assessment to meet MAA requirements

Planned treatment start date for clinically appropriate first-line treatment (and patient’s preferred option)

- Adult onset ambulatory (Type IV). Symptom onset aged 19 or older. The patient takes at least five steps independently in the upright position with the back straight. One leg moves forward while the other supports most of the body weight. There is no contact with a person or object.
- “Walking unaided” (“ambulant” i.e. type III SMA patient): Symptom onset aged 18 or younger. The patient takes at least five steps independently in the upright position with the back straight. One leg moves forward while the other supports most of the body weight. There is no contact with a person or object.
Treatment
Overview
Risdiplam
Nusinersen

TREATMENT OPTIONS
There are two first-line treatments for SMA. Treatment will depend on clinical assessment and patient preference.

RISDIPLAM (EVRYSDI)
Risdiplam is recommended as an option for treating 5q SMA in people aged two months and older with a clinical diagnosis of SMA types 1, 2 or 3 or with pre-symptomatic SMA and 1 to 4 SMN2 copies. It is provided under a Managed Access Agreement (MAA) and recommended only if the conditions of the MAA are followed.

The MAA sets out the conditional reimbursement for risdiplam. It has been developed through a collaboration between NICE, the NHS, SMA REACH and Roche. It is composed of two parts, the Data Collection Agreement (DCA) and the Commercial Access Agreement (CAA).

This drug is a survival motor neuron 2 (SMN2) splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. This small molecule targets and encourages the SMN2 ‘back-up’ gene to produce a greater amount of functional SMN protein, which is lacking in people with SMA.

Risdiplam is an orally-administered liquid designed to provide a sustained increase in SMN protein centrally and peripherally when given daily at home in liquid form by mouth or by feeding tube making it suitable for when patients may not be able to tolerate intrathecal injections or eligible for nusinersen.

- NICE (2021) Risdiplam for treating spinal muscular atrophy in children and adults [TA755]
- NICE tools and resources [TA755]
- Further information about the MAA for risdiplam

In addition to the above comments the Scottish Medicines Consortium have accepted risdiplam for use within NHS Scotland for the treatment of 5q SMA in patients two months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 (survival of motor neuron 2) copies.

(Initial access to risdiplam was through the Early Access to Medicines Scheme (EAMS) which is now closed.)

NUSINERSEN (SPINRAZA)
Nusinersen is provided under a MAA. The drug is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length, more functional SMN protein. Administered intrathecally, it is the first drug to have been licensed for the treatment of 5q SMA. Clinical trials have shown significant improvement in motor function with children who have been treated enabling them to achieve motor milestones that are unprecedented in the natural history of the condition. The drug has demonstrated efficacy in treated children and clinical trials have also highlighted that there may be a benefit in patients who start treatment earlier.

In July 2019, NICE, Biogen and NHS England came to an arrangement for the MAA, which allows children and adults with SMA Types I, II and III to have the treatment in England if they meet access criteria. The MAA is an interim scheme that enables data collection on treatment effectiveness whilst ensuring treatment access. The Spinraza agreement has been granted for five years and currently runs to 2024.

- Further information about the MAA for nusinersen
Referral to SMA clinic – request old notes and genetic report

Video consultation with consultant, physio and nurse

Face-to-face consultation*:
• 30 mins consultant: examination and consent.
• 2 hour assessment with physio and nurse: bloods**, urine protein, respiratory function testing: sniff nasal-inspiratory force, XR lumbar spine or CT spine.
• SMA REACH data input 30 mins (research nurse or physio).
• Referral to respiratory ventilation clinic if no up-to-date assessment.

Patient & MDT* consider treatment options and select risdiplam

Eligibility confirmed through MAA. Register for MAA

Register on SMA REACH database

• Plan treatment start date
• Obtain consent

Baseline assessment

• Prescription for treatment
• Liaise with pharmacy
• Order drug
• Blueteq forms

Patient education on administration and side effects

Drug via homecare delivery or hospital pharmacy

Oral solution taken at same time each day following meal using the reusable oral syringe

Follow-up phone nurse appointment after 1 week to check patient re outcomes & side effects

Assessment every 6 months

*Ensure beforehand all notes and results available and all necessary investigations booked on day and explanation to patient of expectations of visit.
**FBC, U and E, renal function and clotting +/- genetic test to confirm SMN1 mutation and SMN2 copy number.

*Neuromuscular consultant, neuromuscular physiotherapist, pharmacist, neuromuscular nurse specialist

Eligibility confirmed through MAA.

Register for MAA

Comply with data reporting as set out in MAA, assess patient
Overview

**Risdiplam**

**Nusinersen**

**Treatment**

**Assessment**

**Management**

**Resources**

**Glossary**

**Introduction**

**SMA pathway**

**Baseline assessment** set out in MAA: spinal imaging, bloods.

**Compliance with MAA (medical assessment and advice)**

**NDU day case admission: Loading dose by intrathecal infusion**

**Second dose Day 14 (day case)**

**Third dose Day 28 (day case)**

**Fourth dose Day 63 (day case)**

**Maintenance dose at 6 months (day case)**

**Assessment every 6 months (out-patient)**

**Maintenance dose at 10 months (day case)**

**Main tenance dose at 14 months (day case)**

**MDT review at 12 months to assess stabilisation, decline or improvement**

**Eligibility confirmed through MAA. Register for MAA**

**Register on SMA REACH database**

**Referral to SMA clinic – request old notes and genetic report**

**Video consultation with consultant, physio and nurse**

**Face-to-face consultation*:**

- 30 mins consultant: examination and consent.
- 2 hour assessment with physio and nurse: bloods**, urine protein, respiratory function testing: sniff nasal-inspiratory force, XR lumbar spine or CT spine.
- SMA REACH data input 30 mins (research nurse or physio).
- Referral to respiratory ventilation clinic if no up-to-date assessment.

*Ensure beforehand all notes and results available and all necessary investigations booked on day and explanation to patient of expectations of visit.

**Follow-up phone nurse appointment after 1 week to check patient re outcomes & side effects**

**Arrange FBC and clotting renal function and urine protein for next dose**

*(If assessment cannot be done when the patient attends for infusion this may result in an extra visit)*

**NDU = neurology day unit**

**Neuromuscular consultant x 2, neuroradiology consultant & neuromuscular physiotherapist**

**Main maintenance dose at 10 months (day case)**

**Main maintenance dose at 14 months (day case)**

**MRT review at 12 months to assess stabilisation, decline or improvement**

**Referral to SMA clinic – request old notes and genetic report**

**Video consultation with consultant, physio and nurse**

**Face-to-face consultation*:**

- 30 mins consultant: examination and consent.
- 2 hour assessment with physio and nurse: bloods**, urine protein, respiratory function testing: sniff nasal-inspiratory force, XR lumbar spine or CT spine.
- SMA REACH data input 30 mins (research nurse or physio).
- Referral to respiratory ventilation clinic if no up-to-date assessment.

*Ensure beforehand all notes and results available and all necessary investigations booked on day and explanation to patient of expectations of visit.

**Follow-up phone nurse appointment after 1 week to check patient re outcomes & side effects**

**Arrange FBC and clotting renal function and urine protein for next dose**

*(If assessment cannot be done when the patient attends for infusion this may result in an extra visit)*

**NDU = neurology day unit**

**Neuromuscular consultant x 2, neuroradiology consultant & neuromuscular physiotherapist**

**Main maintenance dose at 10 months (day case)**

**Main maintenance dose at 14 months (day case)**

**MRT review at 12 months to assess stabilisation, decline or improvement**

**Referral to SMA clinic – request old notes and genetic report**

**Video consultation with consultant, physio and nurse**

**Face-to-face consultation*:**

- 30 mins consultant: examination and consent.
- 2 hour assessment with physio and nurse: bloods**, urine protein, respiratory function testing: sniff nasal-inspiratory force, XR lumbar spine or CT spine.
- SMA REACH data input 30 mins (research nurse or physio).
- Referral to respiratory ventilation clinic if no up-to-date assessment.

*Ensure beforehand all notes and results available and all necessary investigations booked on day and explanation to patient of expectations of visit.

**Follow-up phone nurse appointment after 1 week to check patient re outcomes & side effects**

**Arrange FBC and clotting renal function and urine protein for next dose**

*(If assessment cannot be done when the patient attends for infusion this may result in an extra visit)*

**NDU = neurology day unit**

**Neuromuscular consultant x 2, neuroradiology consultant & neuromuscular physiotherapist**

**Main maintenance dose at 10 months (day case)**

**Main maintenance dose at 14 months (day case)**

**MRT review at 12 months to assess stabilisation, decline or improvement**

**Referral to SMA clinic – request old notes and genetic report**

**Video consultation with consultant, physio and nurse**

**Face-to-face consultation*:**

- 30 mins consultant: examination and consent.
- 2 hour assessment with physio and nurse: bloods**, urine protein, respiratory function testing: sniff nasal-inspiratory force, XR lumbar spine or CT spine.
- SMA REACH data input 30 mins (research nurse or physio).
- Referral to respiratory ventilation clinic if no up-to-date assessment.

*Ensure beforehand all notes and results available and all necessary investigations booked on day and explanation to patient of expectations of visit.

**Follow-up phone nurse appointment after 1 week to check patient re outcomes & side effects**

**Arrange FBC and clotting renal function and urine protein for next dose**

*(If assessment cannot be done when the patient attends for infusion this may result in an extra visit)*

**NDU = neurology day unit**

**Neuromuscular consultant x 2, neuroradiology consultant & neuromuscular physiotherapist**
Neuromuscular management

A multidisciplinary team approach is the key element in management of people with SMA and the different aspects of care should not be dealt with isolation but as part of a MDT approach. A coordinator should be available to coordinate all aspects of care. The diagnosis and management of SMA recommendations for care highlight an approach for management that addresses the needs of:

• Non-sitters
• Sitters
• Ambulant patients.

The key to all management is a baseline assessment and regular review of the person’s individual ability (see SMA outcome measures and measures evaluated in clinical trials). Any improvement is good.

Rehabilitation: physiotherapy, occupational therapy, speech and language therapy

• Contracture management
• Movement abilitation
• Equipment/adaptations
• Swallow management.

Respiratory rehabilitation and management:

• Baseline respiratory assessments
• Individualised respiratory care plans
• Routine follow up including sleep studies
• When appropriate, use BiPAP and/or cough assist
• Training on management of emergencies.
Orthopaedic management & impact on spine

Regular assessment and review: orthopaedic consultant, physio and OT

Non-sitters
- Reduce impact on tight joints
- Prevent scoliosis
- Postural control and bracing
- Customised upright seating, standing frames
- Thoracic and cervical bracing
- Modifications should include respiratory support. Ensure no restrictions on thoracic expansion / secretion clearance
- Stretching
- Muscle weakness: promote functioning
- Communication
- Cobb angle >20° rechecked 6-monthly until bones no longer growing

Sitters
- Promote function & mobility
- Exercise, e.g. swimming
- Contractures: stretching
- Posture: position & bracing

Ambulant
- Promote function & mobility, lightweight wheelchair, accessible driving

Mobility aids – carry out assessment powered wheelchair / customised seating / vehicle
Respiratory problems adult patients may experience

- Increased secretions
- Impaired feeding and swallow dysfunction
- Increased risk of aspiration (due to swallow dysfunction)
- Poor airway clearance
- Recurrent respiratory infections
- Sleep disordered breathing

Pulmonary assessment, intervention and management
### Pulmonary assessment, intervention and management:

<table>
<thead>
<tr>
<th>Non-sitters</th>
<th>Sitters</th>
<th>Ambulant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of hypoventilation (e.g. transcutaneous CO₂).</td>
<td>Spiriometry.</td>
<td>Review of cough effectiveness.</td>
</tr>
<tr>
<td>Sleep study and overnight oximetry/transcutaneous CO₂ in all symptomatic patients or to determine if NIV initiation needed.</td>
<td>Sleep study and overnight oximetry/transcutaneous CO₂ when minimal suspicion of symptoms of nocturnal hypoventilation.</td>
<td>Where there is suspicion of asthma, a metered dose inhaler +/- a spacer and consideration of inhaled steroid.</td>
</tr>
</tbody>
</table>

**Support airway clearance:**
- Oral suctioning.
- Skilled healthcare professional should implement respiratory therapy immediately: manual chest therapy.
- Cough insufflator/exsufflator (cough assist device).

**Assessments 3 months initially, then 6 monthly.**
- Airway clearance with physiotherapy/respiratory therapy.
- Cough assist essential with ineffective cough.

**Skilled healthcare professional to support manual chest physiotherapy and cough insufflator/exsufflator (cough assist device).**
- Assessments 6 monthly, airway clearance is critical with ineffective cough.

**Clinical physiologist input is essential, particularly for the provision of respiratory function testing, sleep studies and providing NIV with ongoing follow up.**

**Ventilation should be started in all symptomatic patients. Some experts recommend using it during acute respiratory illnesses to facilitate discharge. NIV should be initiated during a sleep study or observing the patient clinically for adequate gas exchange. NIV interfaces should be fitted by skilled physiotherapists selecting two interfaces to alternate skin contact points.**

**Referral to respiratory team if:**
- Evidence of weak cough.
- Recurrent infections.
- Suspicion of nocturnal hypoventilation.

**Monitor patients using mucolytics long term.**

**Source:** Mercuri E, Finkel RS, Muntoni F et al (2017) Diagnosis and management of spinal muscular atrophy
### Physiotherapy and rehabilitation

**Non sitters**

Physiotherapy and rehabilitation aims to reduce impact on tight joints, optimise function and help a patient tolerate different positions, lying or sitting with assistance. Regular assessment from physiotherapist and occupational therapist (OT) is required.

- Positioning, bean bags, wedges and pillows help support non-sitters.
- Custom made seats, reclining or sitting strollers and power chairs help provide support.
- **Stretching**: flexibility is important, utilise:
  - Assisted stretches.
  - Splints to support or immobilise limbs or spine.
  - Splints should be applied for more than 60 minutes or overnight.
  - Braces used to support part of the body for stabilisation – these should be used at least 5 times a week.
- **Neck collars**: helpful for head support and to assist breathing.
- **Standing frames**: used to help maintain and improve posture. They also help with bone health and digestion.
- Exercise and movement in water can be helpful providing the head is well supported and the patient supervised.

**Sitters**

The main objective is to reduce impact and flexibility of tight joints and prevent scoliosis. Physiotherapy and occupational therapy should give guidance and training on how to achieve aims.

- **Orthoses**: to support arms, leg and spine to assist movement or achieve activities such as standing and supported walking.
- **Braces**: to stabilise use minimum x 5 weekly.
- **Splints and braces**: keep joints in certain positions should be worn for 60 mins or overnight.
- **Neck support and supported standing**: stretches legs, promotes good posture increases bone density, blood circulation and eases constipation. 60 mins minimum 3–5 times weekly, 5–7 times is recommended.
- **Stretching**: combining effective stretches with splints and standing exercises is crucial. Routine should be adapted individually by physiotherapy or occupational therapy 5–7 times a week.
- **Mobility and exercise**: all sitters should have a powered wheelchair and custom seating, mobility aids and an accessible car. Exercise will maintain and improve strength, flexibility, resilience and balance and improve participation in school and for leisure and social activities. Resistance training, swimming, horse riding and wheelchair sports are all useful ways to participate in exercise.

**Ambulant**

Involvement of physiotherapy and occupational therapy.

The overall aim is to promote maximum functional independence in day-to-day activities including work, education and recreation. Maintain strength, mobility, balance and range of movement:

- Work on flexibility strength endurance and balance.
- Stretching.
- Positioning.
- Mobility and balance exercise.
- Lightweight manual wheelchairs or ones with power-assisted wheels useful as may be tiring to walk.
- Powered wheelchairs or scooters for long distance.
- Accessible vehicles.
- Ensure accessible environment at home, education and work.
- Improve participation.
- Encourage leisure activities.
Key messages

- Safe swallowing is one of the most important aspects of care as patients with a weak swallow are at risk of inhaling (aspirating) their food which can cause choking and chest (respiratory) infections.
- Review with speech and language therapist annually.
- Standards of Care recommend that a dietician reviews feeding and diet annually.
- If swallowing becomes unsafe, or if the patient is not maintaining their weight, feeding alternatives may be suggested:
  - Short-term options may include feeding through a:
    - Nasogastric (NG) tube - a thin flexible feeding tube passed through the nose into the stomach.
    - Nasojejunal (NJ) tube - through the nose into the middle part of the small intestine (the jejunum).
  - A longer-term option is:
    - Gastrostomy (PEG) tube - placed in the stomach via a surgical procedure and also called a PEG - percutaneous endoscopic gastrostomy. Another procedure called a Nissen Fundoplication, which helps to reduce any reflux, may be done at the same time.
    - NIV team to be involved in gastrostomy.
<table>
<thead>
<tr>
<th>Non-sitters</th>
<th>Sitters</th>
<th>Ambulant</th>
</tr>
</thead>
</table>
| Assessment safe swallowing – bulbar dysfunction can result in aspiration and pulmonary infections. | Assessment of symptoms of dysphagia/aspiration/difficulties with feeding. Video fluoroscopic swallow study if clinical signs suggestive of dysphagia. Nutritional analysis of food records/feeding regimen, longitudinal anthropometrics (height, weight, OFC). Nutrition tabs may be indicated. Acute care monitoring glucose metabolism labs 25 hydroxy-vitamin D tabs, body composition and bone density (DXA). | Dietician assessment  
• See dietitian if over/under nutrition.  
• Nutritional analysis/monitoring if underweight or overweight.  
• Longitudinal anthropometrics (height, weight, BMI, OFC).  
Glucose metabolism labs 25 hydroxy-vitamin D tabs, body composition and bone density. |
| Oral feeding may be limited.                                               | Constipation management – evaluation of fluid and fibre intake recommended for constipation.                        | Bone health important  
• High incidence of osteopenia and fractures.  
• DEXA scan. |
| Interventions – failed swallow study NG tube or NJ tube.                  | Dietician evaluation for concerns of under/over nutrition. Possibility of obesity check BMI. Dietician assessment annually or more often if required. NB Evaluation important for specialised diets. | Speech and language assessment  
• Assessment of symptoms of dysphagia, aspiration, difficulties with feeding.  
• Video fluoroscopic swallow study if suggested by clinical signs suggestive of dysphagia.  
• Nutritional analysis of food records/feeding regimen.  
• Longitudinal anthropometrics (height, weight, OFC).  
• If failed swallow or interventions are not sufficient placement of a long-term gastric feeding tube.  
• If overweight, limit calorie intake and maximise nutrient intake.  
• Minimise fasting during acute care. Appropriate fasting time depends on prior nutritional status and nature of acute event.  
• Provide adequate fluid intake during illness. Monitor electrolyte levels and correct as needed. |
| Adequate hydration and electrolyte balance important during illness.       |                                                                                                                    |                                                                                                                                       |
| Video fluoroscopic swallow study shortly after diagnosis and when suggested by clinical signs suggestive of dysphagia (fatigue, humid voice, pneumonias). Difficulties with eating (pocketing, jaw contractures, increased mealtimes). Nutritional analysis of food records, longitudinal anthropometrics, acute care monitoring 25 hydroxy-vitamin D tabs, body composition and bone density. |                                                                                                                    |                                                                                                                                       |
| Care considerations: Determine appropriate calorie needs based on growth. |                                                                                                                    |                                                                                                                                       |
| Standardised growth charts to track growth trends in combination with body composition measurement tools to assess appropriate growth. |                                                                                                                    |                                                                                                                                       |
| Dietician evaluation annually. NB Evaluation essential important for those on specialised diets. |                                                                                                                    |                                                                                                                                       |

NB. People with SMA are at risk of hypoglycaemia; following period of vomiting or fasting ensure sufficient fluids to prevent ketosis.

Source: Mercuri E, Finkel RS, Muntoni F et al (2017) Diagnosis and management of spinal muscular atrophy
Nutritional care pathway

Nutritional status: assessed annually or more often if problems present

**Low risk**
- Monitor weight, height and BMI
- Swallowing: Rare for ambulant patients to have swallowing and feeding difficulties, but non-sitters and sitters may have NG/NJ/gastric tube in situ.
- Constipation: Can be an issue due to lack of mobility and diet.

**Moderate risk**
- Initiate fortified/high protein, high calorie diet.
- Keep food record chart.
- Encourage milky drinks and appropriate snacks between meals.
- Nutrition risk score.

**High risk**
- Refer to dietitian
- Hypoglycaemia: People with SMA are at risk of hypoglycaemia (low blood sugar) following periods of vomiting or fasting. Ensure sufficient fluids to prevent ketosis.
- Signs of hypoglycaemia: pale, clammy, tired, confused, glazed, not acting as they normally should, unable to wake them.

Monitor weight, height and BMI
- Anyone with elevated BMI should be assessed for possible obesity / excess body fat. Body composition monitored to ensure proportion of bone fat and muscle is healthy. Reduced mobility may result in weight gain.

Swallowing
- Rare for ambulant patients to have swallowing and feeding difficulties, but non-sitters and sitters may have NG/NJ/gastric tube in situ.
- Ensure adequate nutrition.

Constipation
- Can be an issue due to lack of mobility and diet.

Hypoglycaemia
- People with SMA are at risk of hypoglycaemia (low blood sugar) following periods of vomiting or fasting. Ensure sufficient fluids to prevent ketosis.
- Signs of hypoglycaemia: pale, clammy, tired, confused, glazed, not acting as they normally should, unable to wake them.
Acute care

Chest infections and breathing issues are the most frequent problems that require acute or emergency care.

There should be an emergency healthcare plan or illness plan in place written by the medical team including the following information:

- Brief summary of the individual’s diagnosis/es and their understanding of it.
- What are the warning signs or indications that the patient should be taken to hospital?
- Which healthcare providers should be contacted in an emergency?
- A list of regular and PRN medications, and indications for any rescue medications left in the patient’s home for emergency use.
- Any ceilings of care that have been requested by the patient and any that have been recommended by healthcare professionals.
- Describe actions for emergencies arising at home.
- Preferences around respiratory management and preferences for supported breathing i.e. NIV / intubation.
- Any neck or jaw limitations.
- Nutrition and fluids requirements.
- Techniques used for clearing secretions.
- When and which antibiotics should be given.
- Action agreed if resuscitation is required.
- Individual wishes of the patient.

Where possible, local emergency medical services should be contacted in advance to discussed any specific needs and what equipment is used at home. In an emergency, you should go to the closest hospital. Wherever possible, the equipment used at home should also be used, even if this is in an ambulance that is well equipped. Sometimes non-sitters and sitters may need to be transferred between hospitals as they should be cared for at a specialist (tertiary) centre that is equipped to look after them. The clinical team responsible for their long-term care should always be notified about the illness.

See further information about patients requiring anaesthetic.
Further reading

- Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
- NICE (2016) Transition from children’s to adults’ services for young people using health or social care services [NG43]
- NICE (2021) Risdiplam for treating spinal muscular atrophy in children and adults [TA755]
- NICE (2021) Managed Access Agreement: Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
- NICE (2019) Managed Access Agreement – nusinersen 5q SMA
- Care Quality Commission (2014) From the pond into the sea: Children’s transition into adult health services
- Scottish Medicines Consortium (2021) risdiplam 0.75mg/mL powder for oral solution (Evrysdi®)

Organisations

- Muscular Dystrophy UK www.musculardystrophyuk.org
- SMA REACH UK www.smareachuk.org
- Spinal Muscular Atrophy UK www.smauk.org.uk
- Royal College of General Practitioners www.rcgp.org.uk
## Glossary of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BiPAP</td>
<td>Bilevel positive airway pressure</td>
</tr>
<tr>
<td>CT scan</td>
<td>Computerised tomography scan</td>
</tr>
<tr>
<td>EHP</td>
<td>Emergency healthcare plan</td>
</tr>
<tr>
<td>EAMS</td>
<td>Early Access to Medicines Scheme</td>
</tr>
<tr>
<td>EMG</td>
<td>Electromyogram</td>
</tr>
<tr>
<td>MAA</td>
<td>Managed access agreement</td>
</tr>
<tr>
<td>MDT</td>
<td>Multidisciplinary team</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging scan</td>
</tr>
<tr>
<td>NDU</td>
<td>Neurology day unit</td>
</tr>
<tr>
<td>NICE</td>
<td>The National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NIV</td>
<td>Non invasive ventilation</td>
</tr>
<tr>
<td>NG tube</td>
<td>Naso-gastric tube</td>
</tr>
<tr>
<td>NJ tube</td>
<td>Naso-jejunal tube</td>
</tr>
<tr>
<td>NM</td>
<td>Neuromuscular</td>
</tr>
<tr>
<td>OFC</td>
<td>Occipito-frontal circumference</td>
</tr>
<tr>
<td>OT</td>
<td>Occupational therapy</td>
</tr>
<tr>
<td>RSV vaccine</td>
<td>Respiratory syncytial virus vaccine</td>
</tr>
<tr>
<td>SCR</td>
<td>Shared-care record</td>
</tr>
<tr>
<td>SLA</td>
<td>Service level agreement</td>
</tr>
<tr>
<td>SMA</td>
<td>Spinal muscular atrophy</td>
</tr>
</tbody>
</table>
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.

**Transitioning from paediatric to adult care**

In young people with chronic disabilities like SMA, the transition from paediatric to adult care is often difficult if structured and supportive transition programmes are not in place. The transition to adult care is often described as ‘challenging and scary’.

- Learning to navigate a new and complex healthcare system.
- Differences in information provision and expectations.
- Engaging with unfamiliar specialists.
- Difficulty identifying and accessing specialists and multidisciplinary clinics.
- Difficulty accessing funding and equipment.
- Major resource gaps and lack of support navigating the system.

See also:
- Care Quality Commission (2014) From the pond into the sea: Children’s transition into adult health services
- NICE (2016) Transition from children’s to adults’ services for young people using health or social care services [NG43]
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.

Some patients are made aware of treatments by charities and will need to be referred by their GP or neurologist.

**Psychological support and genetic counselling**
- Psychological support for coming to terms with the diagnosis.
- What to expect from treatment and management.
- Genetic counselling, e.g. around family planning.
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.

**GP role**

While the GP is not the primary point of contact for patients because they lack the necessary expertise, they can play a role in SMA care and the relationship is key in terms of delivering a quality service throughout a patient's life. Currently patients tend to bypass GPs altogether and go straight to the paediatric / neuromuscular specialist centre for help. However, with GP education and a comprehensive care plan, GPs can certainly be more engaged in supporting SMA patients with:

- Vitamin D prescription.
- Importance of vaccinations including the specific types (e.g. RSV vaccine, although a change in national guidance is also needed here).
- Antibiotic prescriptions: specialist units should liaise with the patient’s GP on the length of time for antibiotic prescriptions which may vary from normal prescribing. There is a low threshold for SMA patients with frequent chest infections, for example this may need to be a duration of 14 days.

Each patient should have a shared care plan in place which indicates which symptoms they should contact their GP about (with accompanying advice for the GP) and which should be directed towards the paediatric/specialist centre.

Each patient should have a separate emergency care plan.

Community nurses can assist with: providing suction, be available to do swabs or take samples if required, NG replacement, and providing nebuliser machine.

Currently it appears that service level agreements (SLAs) are informal and shared-care records (SCRs) are not in place. This needs to change if there is to be effective working between the specialist centre and local teams.
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.

**Objectives for SMA service**

1. Provide a specialist multidisciplinary neuromuscular service for diagnosis and ongoing management.
2. Initiate appropriate pharmacological and non-pharmacological treatments for patients with SMA.
3. Reduce morbidity and mortality due to SMA including reducing hospitalisation.
4. Ensure equity of access to specialised therapies.
5. Oversee all aspects of care that fall outside the expertise of local units.
6. At an individual level ensure the commissioning service is responsible for minimising disease impact in SMA.
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.

Some patients are made aware of treatments by charities and will need to be referred by their GP or neurologist.

**Audit points**

- **Timing of referrals:**
  - Urgent referral within 1 day to 3 weeks depending on severity.
  - Patient satisfaction questionnaire (local document) covering:
    - Patient made aware of identified timeframes.
    - Contact details at first consultation are made available to patient and their carers.
    - Patient received list of patient information at first consultation.
    - Patient referred for specialist medication (if appropriate) and received information leaflet about the medication detailing side effects and instructions about monitoring.
Patients may already be in the system and enter adult services through a transition pathway or referred in for assessment for one of the treatments now available for SMA.

**Key performance indicators**

- Identified benefit to patients.
  - Equity of access.
  - Appropriate referral pathway based on evidenced-based clinical assessment.
  - Access to the specialist team.
  - Patient has understanding of prognosis, available treatment and outcomes.
- Benefit to health professionals and organisation.
  - Appropriate referral and prioritisation of patient care achieved.
  - Standardisation of assessment and referral process.
  - Relevant investigations and patient information available, reducing delayed patient journey later in pathway.
  - SMA MDT coordinator to liaise and respond directly with health professional and patient/carer regarding referral enquiry, waiting list management and liaise with the appropriate SMA team member to provide supportive information.
  - Cost and time effective management.
  - Clearly defined diagnostic process to follow.
  - Appropriate use of professional expertise and designated discussion time.
  - Clearly defined roles and responsibilities of the health professionals involved in the pathway.
Referral

There may be a video consultation ‘pre-screen’ at this point to establish when the patient was last seen, discuss potential genetic testing to confirm diagnosis and the implications of having treatment.
Assessment for diagnostic confirmation

This may require a genetic test to confirm diagnosis if the patient has not been seen for some time. SMA Type 4, the more common form of adult onset SMA, is most often diagnosed in early adulthood. There are other forms of adult onset SMA with different causes. The impact of adult onset SMA varies greatly between individuals.

Getting a diagnosis of SMA Type 4 or other form of adult onset SMA can take time as the symptoms of SMA can seem similar to the symptoms of other neuromuscular conditions. Waiting for appointments, test results and a diagnosis can be very stressful. If you’re concerned about your symptoms, have had some tests but have not been referred to a consultant neurologist, you might want to request a referral from your GP.

Possible tests are:
- An EMG which shows if the nerve supply is diminished.
- A muscle biopsy which shows if there is any reduction in muscle cells.
- An MRI scan which produces detailed images of the inside of the body.
- A CT scan which is another way of producing detailed images of the inside of the body.
- A range of blood tests, including a blood sample for DNA testing and baseline blood profile.
- Physiotherapy and respiratory assessment may also be required if the patient has not had a review for some time to ensure there are no comorbidities that might impact treatment.
- Baseline physiotherapy assessments prior to starting treatment.

Even with all these tests it’s not always straightforward to say exactly what neuromuscular condition an adult has, though a specific diagnosis of SMA Type 4 can be made following DNA testing.
Established diagnosis

Suspected adult presentation (progressive neuromuscular weakness but not identified as SMA)

Referral for confirmation of diagnosis or treatment assessment

Assessment within 18 weeks

Assessment at NM centre to see if patient suitable to treat

MDT discussion re first-line treatment options

Follow-up discussion about treatment options; patient willing to consider treatment

SMA REACH criteria

Baseline assessment to meet MAA requirements

Planned treatment start date for clinically appropriate first-line treatment (and patient’s preferred option)

Assessment by:
- neurologist,
- neuromuscular consultant,
- Respiratory assessment Physiotherapist,
- CT scan

Psychological support

Discuss any any local research programmes

Follow-up discussions about treatment and/or management options

Discussion about the full implications of intrathecal treatment, the requirement to have this administered in hospital (may necessitate spinal imaging by interventional radiology to assess access) and the impact on the patient’s current routine.
Managed Access Agreements (MAA)

MAAs are a version of conditional reimbursement or coverage with evidence development used in the NHS. They constitute agreements between NHS England and sponsors of new technologies manufacturers that enable new interventions (usually drugs) to become available for a limited time period at a discounted price. These arrangements are co-ordinated by NICE. Clinicians and patient advocacy groups are involved as well as clinical representatives of NHS England.

MAA refers to an arrangement that addresses a significant area of uncertainty in the evidence base as identified by the technology evaluation committee at NICE. MAAs have been used in many single technology appraisals (STAs) and are anticipated for most highly specialised technologies (HST). MAA proposals include an agreed rationale and duration for the arrangement, populations covered (in particular where they come in the care pathway), clear criteria for starting and stopping the new therapy, definition of outcomes, methods of data collection and frequency of reporting, together with a commercial proposition (price discount), financial risk management plans and an understanding of what will happen if reimbursement is eventually withdrawn.


Read more about:
- The MAA for risdiplam
- The MAA for nusinersen
Managed Access Agreement (MAA) for risdiplam

How long will the risdiplam MAA last and what happens then?

It’s anticipated that the Roche will resubmit the new evidence available to NICE in March 2024. The submission will include the data that has been collected from patients throughout the MAA.

The NICE appraisal committee will then evaluate the evidence submissions. They will consider both the clinical and cost effectiveness of the drug and make a final decision on whether risdiplam should continue to be funded on the NHS after the MAA has expired.

- NICE (2021) Managed Access Agreement: Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Read about:
- The MAA for nusinersen
- MAAs in general
SMA REACH

SMA REACH is the UK’s SMA research and clinical hub focused on improving standards of care and translational research. It aims to establish national agreement on medical and physiotherapy assessments, and standards of care for patients with SMA in preparation for future clinical trials in the UK.

Read more on the SMA REACH website

The registry is for individuals living with SM in the UK or Ireland. The patient registry is affiliated to TREAT_NMD Global SMA Registry, which collects anonymised medical information from national SMA registries worldwide. The UK SMA Patient Registry also collaborates with SMA REACH UK (children) and Adult SMA REACH, which are clinical studies that collect doctor-reported data from individuals with SMA. SMA REACH UK is operated by Great Ormond Street Hospital, and Adult SMA REACH by the John Walton Muscular Dystrophy Research Centre, Newcastle. Also participating are the MRC Neuromuscular Centres in London, Newcastle and other neuromuscular centres across the country. SMA REACH studies compliment data provided by patients themselves in the UK SMA Patient Registry. Consent for the exchange of limited and specific patient data between the registry and SMA REACH is requested at registration.

UK SMA Patient Registry
John Walton Muscular Dystrophy Research Centre
Translational and Clinical Research Institute, Newcastle University
International Centre for Life
Newcastle upon Tyne NE1 3BZ
T: 0191 241 8640 E: registries@newcastle.ac.uk
**Risdiplam: Pharmacist independent prescriber role – case study from St George’s Hospital**

- Under the MAA, the pharmacist is the main prescriber. There is now a formalised telephone clinic after the patient’s treatment is confirmed by the MDT. The main role of the pharmacist is to:
  - Confirm the medication history and check for drug interactions.
  - Discuss pharmaceutical issues of risdiplam.
  - Reinforce the principle of disease-modifying treatment (e.g. delay causes further progression to disability).
  - Patients may ask about side effects which is covered by the consultant and the pharmacist reassures and reinforces these messages.
  - Outline the monitoring frequency and ground rules (e.g. ‘no bloods, no drugs’).
  - Determine where they are going to have bloods (if coming to St George’s ensure bloods are ordered for them).
  - Fill out all Blueteq documents.
  - Liaise with pharmacy homecare to provide timely prescriptions.

- If the service has a neuromuscular coordinator this person can take over the administrative tasks.

- The pharmacist independent prescriber, in contrast to nusinersen, performs mostly in a “stepped up” capacity and if not available must be a neuromuscular coordinator.
Homecare

Homecare can be used to supply the drug. Homecare for risdiplam is available via Polar Speed Homecare. This is a dispense and delivery service available to all patients prescribed the drug. Patients are enrolled via their referring centre and contacted by Polar Speed within five days.

The homecare company can reconstitute the drug powder and deliver the resultant oral solution to the patient using cold chain storage. If risdiplam is supplied by the specialist treatment centre, they will:

- Provide sufficient risdiplam to take at home/outside of hospital setting.
- Provide instructions on how bottles can be transported home.
- Provide instructions on how to store and take the medication.
- Supply oral syringes for medicine administration.

If risdiplam is supplied by homecare pharmacy, they will:

- Deliver sufficient risdiplam to the home or previously agreed address.
- Manage the ongoing home deliveries and prescriptions liaising with patients and centres as required.

The patient is also provided with an “Instructions for use for patients/parents and carers” booklet. This booklet gives detailed instructions on how to prepare the dose volume with the re-usable oral syringes provided, and take the medicine either: by mouth, through a gastrotomy tube, or through a nasogastric tube.
Managed Access Agreement (MAA) for nusinersen

The MAA for nusinersen will last for five years, from 24 July 2019 to 23 July 2024. The MAA data collection period will last for a minimum of three years and automatically cease at the end of the fifth year (July 2024), unless NICE guidance is published sooner.

The MAA has been designed to allow enough time for additional evidence to be generated for NICE. At the end of the MAA period, NICE will review the new evidence and review its guidance to indicate whether the medicine should be recommended for use in the NHS – this may result in a difference to what the NHS will pay for the drug for example. While most topics recommended for managed access go on to be recommended for routine use in the NHS, there is no guarantee that it will be recommended when it is reviewed by NICE.

When Biogen resubmits the new evidence available to NICE it will include the data that has been collected from patients throughout the MAA. Patient groups and clinicians can also contribute to this process and make submissions.

The NICE appraisal committee will then evaluate the evidence submissions. They will consider both the clinical and cost effectiveness of the drug and make a final decision on whether nusinersen should continue to be funded in the NHS after the MAA has expired.

- NICE (2019) Managed Access Agreement – nusinersen 5q SMA
  - Contract variation agreement 1, May 2021
  - Contract variation agreement 2, February 2022

Read more about:
- The MAA for risdiplam
- MAAs in general
SMA REACH

SMA REACH is the UK’s SMA research and clinical hub focused on improving standards of care and translational research. It aims to establish national agreement on medical and physiotherapy assessments, and standards of care for patients with SMA in preparation for future clinical trials in the UK.

Read more on the SMA REACH website

The registry is for individuals living with SM in the UK or Ireland. The patient registry is affiliated to TREAT_NMD Global SMA Registry, which collects anonymised medical information from national SMA registries worldwide. The UK SMA Patient Registry also collaborates with SMA REACH UK (children) and Adult SMA REACH, which are clinical studies that collect doctor-reported data from individuals with SMA. SMA REACH UK is operated by Great Ormond Street Hospital, and Adult SMA REACH by the John Walton Muscular Dystrophy Research Centre, Newcastle. Also participating are the MRC Neuromuscular Centres in London, Newcastle and other neuromuscular centres across the country. SMA REACH studies compliment data provided by patients themselves in the UK SMA Patient Registry. Consent for the exchange of limited and specific patient data between the registry and SMA REACH is requested at registration.

UK SMA Patient Registry
John Walton Muscular Dystrophy Research Centre
Translational and Clinical Research Institute, Newcastle University
International Centre for Life
Newcastle upon Tyne NE1 3BZ
T: 0191 241 8640 E: registries@newcastle.ac.uk
**Nusinersen: Pharmacist independent prescriber role – case study from St George’s Hospital**

- **Supply**: The pharmacist is responsible for the dispensed product on the day and for any consumables required (intrathecal needles, syringes). This is a priority area as time is always of the essence.

- **Intrathecal register**: Hospitals like St George’s may have a prescribing register for prescribing, administering, second checking, dispensing, pharmacy checking and provision of nusinersen. Those involved in delivery must be on the register. The consultant is responsible for medical staff and for any independent prescriber to be on register; nurses are responsible for second checkers, the pharmacist is responsible for all pharmacist checkers and pharmacy technicians (dispensing and provision). The pharmacist is responsible for all pharmacy training and accreditation.

- **Intrathecal committee**: The pharmacist has oversight of intrathecal registers and should involve the neurosciences teams including neurosurgery (intrathecal antibiotics). The intrathecal pharmacist also has an important role for baclofen governance.

- **Nusinersen prescription**: The pharmacist is the back-up prescriber if the consultant is on annual leave and can also prescribe post-nusinersen analgesia when needed.

- **Second checker**: The pharmacist is aware of the second checker role. They are able to fill out the second checker Check list (including preparing the nusinersen under sterile conditions in theatre) and are able to step in particularly in service initiation and if no nusinersen nurse is available.

- **Yellow cards**: The pharmacist fills out any yellow cards for adverse reactions.

- **Pharmacist independent prescriber**: As part of their role, the independent prescriber should be able to step up (prescribe nusinersen, act as a second checker in theatre, prescribe post-op analgesia) or step down (to more traditional roles such as dispensing if no accredited pharmacy technicians are available). The accredited personnel pool is small so the independent prescriber should be able to cross boundaries in nursing and medicine in such a way that all professionals are comfortable.
Acute care

Chest infections and breathing issues are the most frequent problems that require acute or emergency care.

There should be an emergency healthcare plan or illness plan in place written by the medical team including the following information:

- Brief summary of the individual’s diagnosis/es and their understanding of it.
- What are the warning signs or indications that the patient should be taken to hospital?
- Which healthcare providers should be contacted in an emergency?
- A list of regular and PRN medications, and indications for any rescue medications left in the patient’s home for emergency use.
- Any ceilings of care that have been requested by the patient and any that have been recommended by healthcare professionals.
- Describe actions for emergencies arising at home.
- Preferences around respiratory management and preferences for supported breathing i.e. NIV / intubation.
- Any neck or jaw limitations.
- Nutrition and fluids requirements.
- Techniques used for clearing secretions.
- When and which antibiotics should be given.
- Action agreed if resuscitation is required.
- Individual wishes of the patient.

Where possible, local emergency medical services should be contacted in advance to discuss any specific needs and what equipment is used at home. In an emergency, you should go to the closest hospital. Wherever possible, the equipment used at home should also be used, even if this is in an ambulance that is well equipped. Sometimes non-sitters and sitters may need to be transferred between hospitals as they should be cared for at a specialist (tertiary) centre that is equipped to look after them. The clinical team responsible for their long-term care should always be notified about the illness.

See further information about patients requiring anaesthetic.

Anaesthetics

If the patient requires an anaesthetic the GP should alert the hospital if this is an elective admission to ensure the team in charge undertake:

- A review of the heart by a cardiologist (only if there is known to be a pre-existing problem).
- A full assessment before any anaesthetics are used. This may include a sleep study and involvement of a dietitian.
- Assessment of difficulties in intubating that may be caused by:
  - Tightening of the jaw
  - Limited neck mobility
  - Difficulties in positioning.
- Monitoring blood carbon dioxide and oxygen at all times, whatever anaesthetic method is used.
- Anticipating any other possible needs such as use of NIV and other breathing interventions.
- Medication for pain management may be needed after an operation.

Considerations of local anaesthesia or regional analgesia; as a general rule anaesthesia does bring challenges.

**Anaesthetics may be used for planned surgery as well as for other reasons, such as administering new drug treatments.**